Bayer Aktiengesellschaft (OTCMKTS:BAYRY) and Genprex (NASDAQ:GNPX) Head to Head Survey

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) and Genprex (NASDAQ:GNPX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Valuation & Earnings

This table compares Bayer Aktiengesellschaft and Genprex”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bayer Aktiengesellschaft	$51.55 billion	0.52	-$3.18 billion	($0.36)	-18.78
Genprex	N/A	N/A	-$30.86 million	N/A	N/A

Genprex has lower revenue, but higher earnings than Bayer Aktiengesellschaft.

Volatility & Risk

Bayer Aktiengesellschaft has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Genprex has a beta of -1.3, meaning that its share price is 230% less volatile than the S&P 500.

Institutional & Insider Ownership

14.1% of Genprex shares are held by institutional investors. 8.5% of Genprex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Bayer Aktiengesellschaft and Genprex, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bayer Aktiengesellschaft	1	8	0	0	1.89
Genprex	0	0	1	0	3.00

Genprex has a consensus target price of $10.00, suggesting a potential upside of 452.49%. Given Genprex’s stronger consensus rating and higher possible upside, analysts plainly believe Genprex is more favorable than Bayer Aktiengesellschaft.

Profitability

This table compares Bayer Aktiengesellschaft and Genprex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bayer Aktiengesellschaft	-2.74%	16.96%	4.95%
Genprex	N/A	-318.57%	-224.95%

Summary

Genprex beats Bayer Aktiengesellschaft on 7 of the 11 factors compared between the two stocks.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

About Genprex

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.